Gene delivery made simple

About us

TraffikGene is a business initiative originating at Universidad de Santiago de Compostela (Spain) focused on the development of a non-viral gene delivery platform based on peptide amphiphiles

TraffikGene Visión


To leverage our proprietary technology platform allowing nucleic acid therapeutics to be delivered efficiently and safely to its site of action.

TraffikGene Misión


To allow the next generation of nucleic acid therapeutics to reach the market faster and with better risk-benefit profiles, reaching patients in need.


Overcoming current gene delivery challenges

We have developed a novel peptide-based gene delivery platform featuring:

-Accelerated vehicle discovery: Structure activity predictability

Single vehicle formulation

Targeting beyond the liver

-Broad cargo versatility

-Patent pending: well differentiated from LNP approaches

High-throughput carrier customization enables optimization for desired delivery characteristics


Validated in vivo data

mRNA admin. route versatility


Tuneable mRNA targeting beyond the liver

Leadership Team

Marisa Juanes

Chief Technology Officer

Ph.D USC, 2019

Alberto Fuertes

Chief Operations Officer

Ph.D USC, 2019

Head of Biology and Biochemistry

Ph.D USC, 2015

Javier Montenegro

Principal Scientist

Ph.D USC, 2009

Chief Executive Officer

McKinsey, Esteve, TreeHill

    Funding & Support

    European Innovation Council - Funded by the European Union

    Funded under Horizon Europe framework – EIC Transition Challenge project TraffikGene-Tx (Ref: 101113110 —  HORIZON-EIC-2022-TRANSITION-01) during the period 06/2023 – 05/2026.